Summary : The FDA has cleared AstraZeneca and Merck & Co’s Lynparza as an adjuvant or neoadjuvant treatment for breast cancer, extending…
March 2022
-
-
AstraZenecaRegulatoryU.S FDA
FDA says no to AZ’s Fasenra for nasal polyp indication
by adminby adminSummary : AstraZeneca has failed in its bid to get US approval for its IL-5 inhibitor Fasenra as a treatment for chronic…
-
Alembic PharmaRegulatoryU.S FDA
Alembic Pharmaceuticals bags USFDA nod for Macitentan tablets
by adminby adminSummary : Alembic Pharmaceuticals received a tentative approval from the United States Food & Drug Administration (USFDA) for its Abbreviated New Drug…
-
Synopsis : Pfizer Inc. (NYSE: PFE) Pfizer stands with the unified global community across the public, private and civil society sectors in…
-
Officials claimed that under the Union Government’s ‘Aroma Mission 2’, 100 farmers from various villages in Chenab valley were taught basic technical…
-
Summary : According to Udayabhaskar, the dedicated Fisheries and Aquaculture Infrastructure Development Fund (FIDF) will aid in the development of infrastructure facilities…
-
Global Market
USDA announced a $250 million fund to encourage new American-made fertiliser, giving farmers in the United States additional options in the market.
by adminby adminSummary : The U.S. Department of Agriculture (USDA) is announcing it will support additional fertilizer production for American farmers to address rising…
-
Agro Science & ResearchGlobal Market
Verde Resources and Rice Tech Nebraska are collaborating to produce carbon-based soil amendment mixes.
by adminby adminSummary : Verde Resources Inc. is a company that specialises in natural resources (OTCQB: VRDR) Verde Renewables, Inc, a fully owned subsidiary…
-
Pharma Science & Research
Mutations leading to omicron variant did not enable virus to fully escape immune system
by adminby adminPeople who gained immunity – either through vaccination or exposure – against the original strain of SARS-CoV-2, the virus that causes COVID-19,…
-
CompaniesNovartis
Novartis signs initial agreement with Carisma Therapeutics for the manufacturing of HER 2 targeted CAR-M cell therapy
by adminby adminSummary : Novartis has signed an initial agreement with Carisma Therapeutics, a biopharmaceutical pioneer in engineered macrophage-based therapeutics, to manufacture the HER…